2.17. Provisions and contingencies
Provision is recognised when the company has a present obligation as a result of past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are determined on the basis of best estimate of the outflow of economic resources required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.
A disclosure of a contingent liability is made when there is a possible obligation or present obligations that may, but probably will not, require an outflow of resources or it cannot be reliably estimated. When there is a possible
obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.
Contingent assets are neither recognised nor disclosed.
2.18. Segmental reporting Identification of segments
Based on the primary segments identified under IRDA (Preparation of Financial Statements and Auditors' Report of Insurance Companies) Regulations 2002 (‘the Regulations') read with AS 17 on “Segmental Reporting” notified under section 133 of the Companies Act 2013 and rules thereunder, the Company has classified and disclosed segmental information separately for Shareholders' and Policyholders'. Within Policyholders', the businesses are further segmented into Participating (Life and Pension), Non-Participating (Life and Pension), Non-Participating variable (Life and Pension), Annuity, Health and Linked (Life, Pension, Health and Group).
There are no reportable geographical segments, since all business is written in India.
Allocation/ Apportionment methodology
The allocation and apportionment of revenue, expenses, assets and liabilities to specific segments is done in the following manner, which is applied on a consistent basis.
• Revenue, expenses, assets and liabilities that are directly identifiable to the respective segments, are allocated on actual basis;
• Other revenue, expenses (including depreciation and amortisation), assets and liabilities that are not directly identifiable to a respective segment are apportioned based on one or combination of some of the relevant drivers which includes:
• Number of policies
• Number of claims
• Annualised premium since inception
• Sum assured
• Premium income
• Medical cases
• Funds under management
• Commission
• Total operating expenses (for assets and liabilities)
• Use of asset (for depreciation expense)
The accounting policies used in segmental reporting are the same as those used in the preparation of financial statements.
2.19. Foreign exchange transactions
Initial recognition: Foreign currency transactions are recorded in Indian Rupees, by applying to the foreign currency amount the exchange rate between the Indian Rupee and the foreign currency at the date of the transaction.
Conversion: Foreign currency monetary items are translated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency, are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.
Exchange differences: Exchange differences arising on such conversions are recognised as income or as expenses in the period in which they arise either in the Revenue Account or the Profit and Loss Account, as the case may be.
2.20. Earnings per share
Basic earnings per share are calculated by dividing the profit or loss after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the profit or loss after tax for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares which could have been issued on the conversion of all dilutive potential equity shares.
Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value. Dilutive potential equity shares are determined independently for each period presented.
2.21. Cash and Cash Equivalents
Cash and cash equivalents for the purpose of Receipts and Payments account include cash and cheques in hand, bank balances, liquid mutual funds and other investments with original maturity of three months or less which are subject to insignificant risk of changes in
value. Receipts and Payments Account is prepared and reported using the Direct Method in accordance with Accounting Standard (AS) 3, “Cash Flow Statements” as per requirements of Master Circular of IRDAI (Preparation of Financial Statements and Auditors' Report of Insurance Companies) regulations, 2002.
2.22. Unclaimed amount of policyholders
The unclaimed amount of policyholders is governed by the IRDAI Master circular no. IRDA/F&A/CIR/ Misc/282/11/2020 dated November 17, 2020, and Investment Regulations, 2016 as amended from time to time. The Company maintains a single segregated fund to manage all unclaimed amounts.
Unclaimed amount of policyholders' liability is determined on the basis of NAV of the units outstanding as at the valuation date.
Assets held for unclaimed amount of policyholders and unclaimed amount of policyholders' liability are considered as current assets and current liabilities, respectively and are disclosed in Schedule 12 “Advances and Other Assets” and Schedule 13 “Current Liabilities”.
Income on unclaimed amount of policyholders is accreted to the unclaimed fund and is accounted for on an accrual basis, net of fund management charges, and is disclosed under the head “Interest on unclaimed amounts” in Schedule 4 “Benefits paid” in Revenue account.
The unclaimed of policyholders except litigation cases which are more than 120 months as on 30th September every year, are transferred to the Senior Citizens' Welfare Fund (SCWF) on or before 1st March of that financial year.
3.2. Pending litigations
The Company's pending litigation comprises of claims against the Company primarily by the customers and proceedings pending with Tax authorities. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed the contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a material adverse effect on its financial statements at March 31, 2024. Refer note 3.1 for details on contingent liabilities.
In respect of litigations, where the management assessment of a financial outflow is probable, the Company has made a provision of ' 1,218,562 thousand at March 31, 2024 (March 31, 2023: ' 1,077,754 thousand).
3.3. Actuarial method and assumptions
The actuarial liability in respect of both participating and non-participating policies is calculated using the gross premium method, using assumptions for interest, mortality, morbidity, persistency, expense, inflation and in the case of participating policies, future bonuses together with allowance for taxation and allocation of profits to shareholders. These assumptions are determined as prudent estimates at the date of valuation including allowances for possible adverse deviations.
The liability for the unexpired portion of the risk for the non-unit liabilities of linked business and attached riders is the higher of the liability calculated using discounted cash flows and the unearned premium reserve.
An unexpired risk reserve and a reserve in respect of claims incurred but not reported is held for contracts wherein there is a possibility of lag in intimation of claims.
The unit liability in respect of linked business is the value of the units standing to the credit of policyholders, using the Net Asset Value (‘NAV') prevailing at the valuation date.
A brief of the assumptions used in actuarial valuation is as below:
a) The interest rates used for valuing the liabilities are in the range of 5.04% to 6.56% per annum. The interest rates used at March 31, 2023 were in the range of 4.99% to 6.58%per annum.
b) Mortality rates used are based on the published “Indian Assured Lives Mortality (2012 - 2014) Ult.” mortality table for assurances and “Indian Individual Annuitant's Mortality Table (2012-15)” table for annuities adjusted to reflect expected experience. Morbidity rates used are based on CIBT 93 table, adjusted for expected experience, or on risk rates provided by reinsurers.
c) Expenses are provided for at least at the current levels in respect of renewal expenses, with no allowance for any future improvement.
d) Per policy renewal expenses are assumed to inflate at 4.91% per annum. The expense inflation assumption used at March 31, 2023 was 4.90%.
e) The bonus rates for participating business to be declared in the future is consistent with the valuation assumptions.
f) The tax rate applicable for valuation at March 31, 2024 is 14.56% per annum. The tax rate applicable for valuation at March 31, 2023 was 14.56% per annum.
Certain explicit additional provisions are made, which include the following:
a) Reserves for additional expenses that the Company may have to incur if it were to close to new business twelve months after the valuation date.
b) Reserves for guarantees available to individual and group insurance policies.
c) Reserves for cost of non-negative claw back additions.
d) Reserves for free look option given to policyholders calculated using a free look cancellation rate of 2.00% as on March 31, 2024. The free look cancellation assumption used at March 31, 2023 was 2.30%.
e) Reserves for lapsed policies eligible for revivals.
f) An additional reserve is held for incurred but not reported claims.
3.4. Funds for Future Appropriations (‘FFA’)
The balance of participating FFA of ' 12,865,780 thousand (March 31, 2023: ' 16,692,745 thousand) is not available for distribution to the shareholders. Such amount is classified under Funds for Future appropriations in the Balance Sheet.
3.5. Claims settled and remaining unpaid
Claims settled and remaining unpaid for a period of more than six months at March 31, 2024 is ' 68,652 thousand (March 31, 2023: ' 73,399 thousand). These claims remain unpaid awaiting receipt of duly executed discharge documents from the claimants or litigation pending.
3.6. Reconciliation of unclaimed amounts of policyholders
The unclaimed amount of policyholders is governed by the IRDAI Master circular no. IRDA/F&A/CIR/ Misc/282/11/2020 dated November 17, 2020 and Investment Regulations, 2016 as amended from time to time. The Company maintains a single segregated fund to manage all unclaimed amounts.
The amount in the unclaimed fund has been disclosed in schedule 12 as “Assets held for unclaimed amount of policyholders”. Investment income accruing to the unclaimed fund has been credited to the fund and disclosed as ‘Other Income under Linked Life segment in the Revenue Account. Such investment income net of fund management charges (‘FMC') is paid/ accrued as “interest on unclaimed amounts” in schedule 4 of the financial statements as “Benefits paid”.
3.9. Taxation
The current tax provision is determined in accordance with the provisions of Income Tax Act, 1961. The provision for current tax for the year ended March 31, 2024 is ' 1,786,608 thousand (March 31, 2023: ' 2,704,537 thousand).
The provision for current tax includes an amount of ' 1,078,201 thousand for the year ended March 31, 2024 (March 31, 2023: ' 1,842,258 thousand) which has been charged on the total surplus of the participating line of business in Revenue Account, in line with the Company's accounting policy.
Further, tax expense amounting to ' 708,407 thousand for the year ended March 31, 2024 (March 31, 2023: ' 862,279 thousand) pertaining to other than participating line of business has been charged to Profit & loss account.
3.10. Operating lease commitments
The Company takes premises, motor vehicles, office equipments and servers on operating lease. Certain lease arrangements provide for cancellation by either party and also contain a clause for renewal of the lease agreement. Lease payments on cancellable and non-cancellable operating lease arrangements are charged to the Revenue account and the Profit and Loss account over the lease term on a straight line basis. The total operating lease rentals charged for the year ended March 31, 2024 is ' 806,243 thousand (March 31, 2023: ' 689,074 thousand).
Lease rentals pertaining to non-cancellable leases charged to the Revenue account and the Profit and Loss account for the year ended March 31, 2024 is ' 30,656 thousand (March 31, 2023: ' 30,905 thousand). The future minimum lease payments in respect of these non-cancellable leases at the Balance Sheet date are summarised below:
3.11. Assets given on operating lease
The Company has entered into an agreement in the nature of leave and license for leasing out the investment property. This is in the nature of operating lease and lease arrangement contains provisions for renewal. There are no restrictions imposed by lease arrangement and the rent is not determined based on any contingency. The total lease payments received in respect of such lease recognised in the Revenue account and the Profit and Loss account for the year ended March 31, 2024 is ' 458,093 thousand (March 31, 2023: ' 370,091 thousand).
(b) Defined benefit plans (i) Gratuity
General description of defined benefit plan
This is a funded defined benefit plan for qualifying employees under which the Company contributes to the ICICI Prudential Life Insurance Company Limited Employees' Group Gratuity Cum Life Assurance Scheme. The plan provides for a lump sum payment as determined in the manner specified under the Payment of Gratuity Act, 1972 or the Company's gratuity scheme, whichever is higher, to the vested employees. The benefit vests after a minimum prescribed period of continuous service at retirement or on death while in employment or on termination of employment. Defined benefit obligations are actuarially determined at each quarterly Balance Sheet date using the projected unit credit method as required under Accounting Standard (AS) 15 (Revised), “Employee benefits”. Actuarial gains or losses are recognised in the Revenue Account.
3.19. Employee Stock Option Scheme (“ESOS”)
The Company granted options to its employees under its Employees Stock Option Scheme, prior to listing, since approval of its Employees Stock Option Scheme - 2005. This pre-IPO Scheme shall be referred to as ‘ESOS 2005' or ‘Scheme'. The Scheme had six tranches namely Founder, 2004-05, 2005-06, 2006-07, Founder II and 2007-08, pursuant to which shares had been allotted and listed in accordance with the in-principle approval extended by the stock exchanges. All six tranches under the pre-IPO Scheme stand lapsed as on March 31, 2024. The Scheme had been instituted vide approval of its Members at the Extra-Ordinary General Meeting (EGM) dated March 28, 2005 and had been subsequently amended by the Members of the Company vide its EGM dated February 24, 2015.
The Scheme was ratified and amended by the members of the Company at its Annual General Meeting held on July 17, 2017 which is in compliance with the SEBI (Share Based Employee Benefits) Regulations, 2014 (referred to as the ‘Revised Scheme').
The meeting of Board Nomination and Remuneration Committee (BNRC) and the Board held on April 24, 2019 had approved the amendment to the definition of “Exercise Period”. The revision to the definition was approved by the members of the Company at its Annual General Meeting held on July 17, 2019.
Further, the meeting of BNRC and the Board held on April 17, 2021 and April 19, 2021 respectively had approved the increase in the limit of the number of shares issued or issuable since March 31, 2016 pursuant to the exercise of any
Options granted to the Eligible Employees issued pursuant to the Revised Scheme or any other stock option scheme of the Company, by 0.90% of the number of shares issued as on March 31, 2016, i.e. from a limit of 2.64% of the number of shares issued as on March 31, 2016 to 3.54%. The revision to the limit was approved by the members of the Company at its Annual General Meeting held on June 25, 2021.
As per the Revised Scheme, the aggregate number of shares issued or issuable since March 31, 2016 pursuant to the exercise of any Options granted to the Eligible Employees issued pursuant to the Scheme or any other stock option scheme of the Company, shall not exceed 3.54% of the number of shares issued at March 31, 2016. Further, pursuant to the Revised Scheme the maximum number of Options that can be granted to any Eligible Employee in a financial year shall not exceed 0.1% of the issued Shares of the Company at the time of grant of Options. The Revised Scheme provides for a minimum period of one year between the grant of Options and vesting of Options. The exercise price shall be determined by the BNRC in concurrence with the Board of Directors of the Company on the date the options are granted and shall be reflected in the award confirmation. Shares are allotted/issued to all those who have exercised their Options, as granted by the Board of the Company and/or the BNRC in accordance with the criteria ascertained pursuant to the Company's Compensation policy.
The Company granted options in seventeen more tranches under ESOS 2005 (Revised), namely 2017-18, 2018-19, 2018-19 special options, 2018-19 joining options, 2019-20, 2019-20 joining options, 2020-21, two tranches of 202021 joining options, 2021-22 three tranches of 2021-22 joining options, 2022-23, 2022-23 joining options, 2023-24, 2023-24 joining options.
The Company follows intrinsic value method and hence there was no charge in the Revenue Account and the Profit and Loss account on account of new grants during the year.
3.20. Foreign exchange gain/loss
Transactions in foreign currencies are recorded at exchange rate prevailing on the date of transaction. The exchange difference between the rate prevailing on the date of transaction and on the date of settlement is recognised as income or expense, as the case may be. The net foreign exchange fluctuation loss debited to the Revenue account and the Profit and Loss account for the year ended March 31, 2024 is ' 9,708 thousand (March 31, 2023: ' 8,721 thousand).
3.21. Earnings per share
Basic earnings per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for effects of all dilutive equity shares.
3.22. Managerial Remuneration
The appointment of managerial personnel is in accordance with the requirements of Section 34A of the Insurance Act, 1938. IRDAI has issued guidelines on June 30, 2023 on remuneration of Non-Executive Directors and Managing Director (‘MD') /Chief Executive Officer (‘CEO') /Whole Time Directors (‘WTD'), which have prescribed certain qualitative and quantitative disclosures. The disclosures for year ended March 31, 2024, are given below:
Remuneration to MD/CEO/WTD:
Qualitative disclosures:
A) Information relating to the bodies that oversee remuneration.
Name, composition and mandate of the main body overseeing remuneration:
The Board Nomination and Remuneration Committee (BNRC/Committee) is the body which oversees aspects pertaining to remuneration. The functions of the Committee include identifying persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down and recommending to the Board their appointment & removal and formulating a criteria and specifying the manner for effective evaluation of every individual director's performance, evaluation of the performance of the Board and its Committees, and reviewing its implementation and compliance; considering to extend or continue the term of appointment of the Independent Directors, on the basis of the report of performance evaluation of Independent Directors; recommending to the Board a policy relating to the remuneration for the
Directors, key management persons and other employees; recommending to the Board all remuneration, in whatever form, payable to senior management; ensuring that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully; ensuring that the relationship of remuneration to performance is clear and meets appropriate performance benchmarks; approving the compensation program and ensuring that remuneration to Directors, key management persons and senior management involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company and its goals; formulating the criteria for determining qualifications, positive attributes and independence of a Director; devising a policy on diversity of the Board; considering and approving employee stock option schemes and administering & supervising the same; ensuring that the proposed appointments/re-appointments of key management persons or Directors are in conformity with the Board approved policy on retirement/superannuation; scrutinising the declarations of intending applicants before the appointment/re-appointment/election of Directors by the shareholders at the annual general meeting; and scrutinising the applications and details submitted by the aspirants for appointment as the key management person.
External consultants whose advice has been sought, the body by which they were commissioned and in what areas of the remuneration process:
The Company employed the services of reputed consulting firms for market benchmarking in the area of compensation.
Scope of the Company’s remuneration policy (e.g. by regions, business lines), including the extent to which it is applicable to foreign subsidiaries and branches:
The Company's Policy on Compensation & Benefits (“Compensation Policy”) for Managing Director & CEO, Other wholetime Directors, non-executive Directors, Key Management Person (KMP), Senior Management Personnel (SMP) and other employees was last amended and approved by the BNRC and the Board at its Meeting held on October 14, 2023 and October 17, 2023 respectively.
Type of employees covered and number of such employees:
All employees of the Company are governed by the Compensation Policy. The total number of permanent employees governed by the Compensation Policy of the Company at March 31, 2024 was 18,844.
B) Information relating to the design and structure of remuneration process.
Key features and objectives of remuneration policy:
The Company has historically followed prudent compensation practices under the guidance of the Board and the BNRC. The Company's approach to compensation is based on the ethos of meritocracy and fairness within the framework of prudent risk management. This approach has been incorporated in the Compensation Policy, the key elements of which are given below:
Effective governance of compensation:
The Company follows prudent compensation practices under the guidance of the BNRC and the Board. The BNRC has the oversight for framing, review and implementation of the Company's Compensation Policy on behalf of the Board, and shall work in close coordination with the Board Risk Management Committee for an integrated approach to the formulation of the Compensation Policy where required .The decision relating to the remuneration of the Managing Director and CEO (MD & CEO) , other wholetime Directors and KMPs/SMPs is reviewed and approved by the BNRC and the Board. The BNRC and the Board approves the Key Performance Indicators (KPIs) and the performance threshold for payment of performance bonus, if applicable. The BNRC assesses business performance against the KPIs and on various risk parameters as prescribed by IRDAI. Based on its assessment, it makes recommendations to the Board regarding compensation for MD & CEO and other wholetime Directors, performance bonus and longterm pay for all eligible employees, including senior management and key management persons.
Alignment of compensation philosophy with prudent risk taking:
The Company seeks to achieve a prudent mix of fixed and variable pay, with a higher proportion of variable pay at senior levels. For the MD & CEO and other wholetime Directors and KMPs/SMPs, compensation is sought to be aligned to both pre-defined performance objectives of the Company as well as prudent risk parameters. In addition,
the Company has an Employees Stock Option Scheme and an Employee Stock Unit Scheme aimed at enabling employees to participate in the long-term growth and financial success of the Company through stock option grants/stock unit grants that vest over a period of time.
Whether the Remuneration Committee reviewed the firm’s remuneration policy during the past year, and if so, an overview of any changes that were made:
The BNRC reviewed the Company's Compensation Policy at its meetings held on April 20, 2023, July 15, 2023 and October 14, 2023 respectively.
• Insurance Regulatory and Development Authority of India(IRDAI)hadreleased'GuidelinesonRemuneration of Directors and Key Management Persons of Insurers' (‘Compensation Guidelines') on June 30, 2023, with the objective of promoting the alignment of remuneration policies with the long-term interest of insurers to avoid excessive risk taking, thereby promoting sound overall governance of insurers and fair treatment of customers. These guidelines are applicable for remuneration payable to whole-time Directors (WTDs), Key Management Persons (KMPs) and Senior Management Persons (SMPs) of private insurers from Financial Year 2023-24.
• A comprehensive evaluation was undertaken of the Compensation Policy for compliance, consistency, and structure, and accordingly a new policy was proposed to the Committee, in line with the Compensation Guidelines. The key changes involved including a detailed section on effective governance of compensation, changes to the definition of variable pay for WTDs/KMPs/SMPs to include performance bonus and/or share-linked instruments, such as employee stock options or employees' stock units, changes to the composition, mix and deferral of variable pay for WTDs/KMPs/SMPs, alignment of compensation to defined parameters & weightages to align compensation with the long-term interest of the Company for WTDs/KMPs/SMPs, malus and claw-back provisions for employees at levels where long-term pay is granted (including for deterioration of financial performance of the Company for WTDs/KMPs/SMPs), age & tenure restrictions for the MD & CEO, other WTDs and non-executive Directors, specific guidelines for compensation of staff in control functions, and enhanced disclosure & accounting requirements.
The revised compensation policy was approved by the BNRC and the Board at its meetings held on July 15, 2023 and July 18, 2023 respectively.
The policy was further amended by the BNRC and the Board in October 2023 to include a clause on age and tenure of the MD & CEO, WTDs and KMPs/SMPs.
Description of the ways in which current and future risks are taken into account in the remuneration processes.
• The Company follows prudent compensation practices under the guidance of the Board and the Board Nominations & Remuneration Committee (BNRC). The Company's approach to compensation is based on the ethos of meritocracy and fairness within the framework of prudent risk management. The performance rating assigned to employees is based on an assessment of performance delivered against a set of defined performance objectives. These objectives are balanced in nature and comprise a holistic mix of financial, customer, people, process, quality, compliance objectives and/ or any other parameters as may be deemed fit.
• For the MD & CEO and other wholetime Directors and KMPs/SMPs, compensation is sought to be aligned to both pre-defined performance objectives of the Company as well as prudent risk parameters.
• For the MD & CEO and other wholetime Directors and KMPs/SMPs, the quantum of bonus does not exceed a certain percentage (as stipulated in the Compensation Policy) of total fixed pay in a year; a minimum of 50% (as stipulated in the Compensation Policy) will be under deferment. If the bonus amount is under ' 25 lakhs, the deferment shall not be applicable. The deferral period would be spread over a minimum period of three years (deferment period). The frequency of vesting will be on annual basis and the first vesting shall not be before one year from the commencement of deferral period. The vesting shall be no faster than a prorata basis. Additionally, vesting will not be more frequent than on a yearly basis.
• The deferred part of the variable pay (performance bonus and long term pay in the form of stock options/ stock units) for wholetime Directors and KMPs/SMPs
is subject to malus, under which, the Company will prevent vesting of all or part of the variable pay in the event of an enquiry determining gross negligence or integrity breach.
• In malus clawback arrangements with wholetime Directors and KMPs/SMPs, the employee agrees to return, in case asked for, the previously paid variable pay to the Company in the events as stated in the Compensation Policy including gross negligence, misconduct, integrity breach, deterioration in financial performance.
• Errors of judgment shall not be construed to be breaches.
Description of the ways in which the Company seeks to link performance during a performance measurement period with levels of remuneration.
The Company's approach to compensation is based on the ethos of meritocracy and fairness within the framework of prudent risk management. The extent of variable pay for individual employees is linked to individual performance for sales frontline employees and to individual & organisation performance for non-sales frontline employees & employees in the management cadre. For the latter, the performance rating assigned is based on assessment of performance delivered against a set of defined performance objectives. These objectives are balanced in nature, and comprise a holistic mix of financial, customer, people, process, quality and compliance objectives and/ or any other parameters as may be deemed fit. For the MD & CEO , other wholetime Directors and KMPs/SMPs to ensure effective alignment of compensation with prudent risk parameters, the Company takes into account various risk parameters along with other pre-defined performance objectives of the Company.
3.25. Investments
a. The investments are made from the respective funds of the Policyholder's or Shareholder's and investment income thereon has been accounted accordingly.
b. All investments are performing investments.
3.26. Interest rate derivatives
In line with the requirement of IRDAI Investment Master circular, the Company has put in place a derivative policy approved by Board. The policy covers various aspects substantiating the hedge strategy to mitigate the interest rate risk, thereby managing the volatility of returns from future fixed income investments due to variations in market interest rates.
A) The Company has during the period, as part of its hedging strategy, entered into Forward Rate Agreements (FRA) transactions to hedge the interest rate sensitivity for highly probable forecasted transactions as permitted by the IRDAI Investment Master Circular. The FRA derivative contracts are over-the-counter (OTC) transactions, agreeing to buy notional value of a debt security at a specified future date, at a price determined at the time of the contract with an objective to lock in the price of an interest bearing security at a future date.
D) A net amount of ' 132,716 thousand for the year ended March 31, 2024 (March 31, 2023: ' 1,029,473 thousand) was recognised in Revenue Account being the portion of loss determined to be ineffective portion of the effective hedge. The amount that was removed from the cash flow hedge reserve account during the year ended March 31, 2024 in respect of forecast transaction for which hedge accounting had previously been used but is no longer expected to occur is ' Nil (March 31, 2023: Nil). The hedged forecast transactions are expected to occur over the outstanding tenor of underlying policy liabilities and corresponding hedging gain/loss will accordingly flow to the Revenue Account
E) Disclosures on risk exposure in Interest rate derivatives:
i. Interest rate derivative hedging instruments: Derivatives are financial instruments whose characteristics are derived from the underlying assets, or from interest and exchange rates or indices. Interest rate derivatives include forward rate agreements, interest rate swaps and interest rate futures. The Company during the financial year has entered into forward rate agreement (FRA) derivative instrument to hedge exposure due to interest rate sensitivity for highly probable forecasted transactions. These hedges were entered only for hedging purpose to hedge the interest rate risk. This hedge is carried in accordance with its established policies, strategy, objective and applicable regulations.
ii. Derivative policy, process and hedge effectiveness assessment: The Company has a well-defined Board approved derivative policy and standard operating procedures setting out the strategic objectives, regulatory and operational framework and risks associated with interest rate derivatives. The policy includes the risk measurement and monitoring, processes to be followed and controls thereon. The accounting treatment has been documented and ensures a process of periodic effectiveness assessment and accounting in accordance with applicable accounting standard issued by the Institute of Chartered Accountants of India (ICAI).
The Company has clearly defined roles and responsibilities to ensure independence and accountability through the investment decision, trade execution, to settlement, accounting and periodic reporting and audit of the Interest rate derivative exposures. The overall policy, risk management framework for the Interest rate derivatives are monitored by the Board Risk Management Committee.
iii. Scope and nature of risk identification, risk measurement, and risk monitoring: The derivative policy as approved by the Board identify risk associated with interest rate derivatives transactions and sets appropriate market risk limits such as stress testing and value-at-risk limits. Financial risks of the derivative portfolio are measured and monitored on periodic basis.
272 193 Management Report 203 Independent Auditors' Report and Certificates 214 Revenue Account 216 Profit & Loss Account 217 Balance Sheet
Nex
3.28. Valuation of Investment property
In accordance with the IRDAI Regulations, 2002 (Preparation of Financial Statements and Auditors' Report of Insurance Companies), the Company's investment property has been revalued. The Company has revalued all its investment properties held for more than one year and market value for such properties is based on valuation performed by an independent valuer at March 31, 2024. The opinion on market value by the independent valuer, is prepared in accordance with the “The RICS Valuation Standards” published by the Royal Institution of Chartered Surveyors
(“RICS”), subject to variation to meet local established law, custom, practice and market conditions. The methods used in valuation of property includes “Direct comparable approach”. The real estate investment property is accordingly valued at ' 4,982,990 thousand at March 31, 2024 (March 31, 2023: ' 4,893,040 thousand). The historical cost of the property at March 31, 2024 is ' 4,191,408 thousand (March 31, 2023: ' 4,191,408 thousand).
3.29. Impairment of investment assets
In accordance with the Financial Statements Regulations, Schedule A Part I on “Accounting Principle for Preparation of Financial Statements” on procedure to determine the value of investment and the relevant circular, the impairment in value of investments other than temporary diminution has been assessed as at March 31, 2024 and accordingly impairment provisions/(reversal) have been provided as below.
Listed and Unlisted Equity Shares
In case of Listed Equity Shares, a provision/(reversal) for impairment loss has been recognized in Revenue Account and Profit and Loss Account under the head “Provision for diminution in the value of investments”. Policyholders' and Shareholders' Fair Value Change Account under Policyholders' and Shareholders' Funds respectively in the Balance Sheet have been adjusted for such provision/(reversal) of impairment loss. The details of impairment for the year are given below:
3.43. Extra allocation
As per the product filing for Group Unit Linked Superannuation and Group Unit Linked Employee Benefit Plan, extra allocation of units made and total extra allocation recovered is disclosed as below.
Total extra allocation made with respect to group products (Group Unit Linked Superannuation and Group Unit Linked Employee Benefit Plan) for the year ended March 31, 2024 is ' 1,424 thousand (for year ended March 31, 2023: ' 1,200 thousand).
The amount of recovery towards extra allocation for the year ended March 31, 2024 is ' 2389 thousand (March 31, 2023: ' 479 thousand).
3.44. Dividend
Final dividend proposed for year ended March 31, 2024 is ' 0.60 per equity share (year ended March 31, 2023: ' 0.60 per equity share) of ' 10 each in its board meeting held on April 23, 2024, subject to shareholder approval in annual general meeting.
Unclaimed dividend of ' 6,312 thousand at March 31, 2024 (March 31, 2023: ' 7,621 thousand) represents dividend paid but not claimed by shareholders, and are represented by a bank balance of an equivalent amount.
3.48. Long term contracts
The Company has a process whereby periodically all long term contracts are assessed for material foreseeable losses. At the year end, the Company has reviewed and ensured that adequate provision as required under any law / accounting standards for material foreseeable losses on such long term contracts including derivative contracts has been made in the financial statements.
For insurance contracts, actuarial valuation of liabilities for policies is done by the Appointed Actuary of the Company. The methods and assumptions used in valuation of liabilities are in accordance with the regulations issued by the Insurance Regulatory and Development Authority of India ("IRDAI") and actuarial practice standards and guidance notes issued by the Institute of Actuaries of India.
3.49. Corporate Social Responsibility
As per section 135 of the Companies Act, 2013 and amendment rules, the amount required to be spent by the Company on Corporate Social Responsibility (CSR) related activities during the year ended March 31, 2024 was ' 26,433 thousand (March 31, 2023: ' 38,807 thousand).
3.50. Loans and advances to subsidiaries, associates and related entities
Pursuant to Securities and Exchange Board of India (Listing obligations and disclosure requirements) Regulations, 2015, disclosures pertaining to loans and advances given to subsidiaries, associates and related entities are given below:
There are no loans and advances given to subsidiaries, associates and firms/companies in which directors are interested except for advances which are in the normal course of business but not in the nature of loans (March 31, 2023: ' Nil)
7
n
There are no investments by the loanee in the shares of the Company. c
3.51. Contribution to Policyholders’ account Expense of Management
In accordance with the Insurance Regulatory and Development Authority of India (Expenses of Management, including Commission, of Insurers) Regulations, 2024 expense of management in excess of allowable limit in Participating and Non Participating (including linked) business segment is required to be borne by the Shareholders' and separately disclosed in the Profit and Loss account & the Revenue Account.
The Company is in compliance with the expense of management regulation for Participating and Non Participating (including linked) business segment and also at an overall level during the year ended March 31, 2024. Further, in the Non-par line of business, during the year ended March 31, 2023, expense of management in excess of allowable limits amounting to ' 2,655,997 thousand was charged in the Profit and Loss account and was separately disclosed.
3.52. Ind AS Implementation
Pursuant to IRDAI letter 100/2/Ind AS- Mission Mode/2022-23/1 dated July 14, 2022, a disclosure on the strategy for Ind AS implementation and progress in this regard is given below:
In January 2020, IRDAI issued a circular stating that the effective implementation date of Ind AS in the Indian insurance sector would be decided after the finalisation of IFRS 17 by International Accounting Standards Board (IASB). In June 2020, IASB notified the amended IFRS 17 with an effective date on or after January 1, 2023. In February 2022, ICAI issued an exposure draft of amendments to Ind AS 117 - Insurance Contracts, aligning it with IFRS 17. The amended Ind AS 117 is currently awaiting formal notification.
Further, during FY2024, the company received communication from IRDAI regarding the phased implementation of IFRS/IND AS in the insurance sector and the Company has been identified under phase 1 Insurer Category to implement Ind AS from April 1, 2025.
The Company has implemented IFRS 17 as part of consolidation for its foreign promotor and has prepared the opening balance sheet at January 1, 2022 as well as the financial statements for the year ended December 31, 2022 and December 31, 2023. The Company expects to leverage this experience to comply with any additional requirements that may be stipulated in the final notification of Ind AS 117 and Ind AS 109.
3.53. Loans, Advances & Investment by or on behalf of Ultimate Beneficiaries
a) The Company has not advanced or loaned or invested (either from borrowed funds or share premium or any other sources or other kind of funds) to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
b) The Company has not received any funds (which are material either individually or in the aggregate) from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
3.54. Previous year comparatives
Previous year's figures have been regrouped and reclassified wherever necessary to conform to current year's presentation.
As per our report of even date attached. For and on behalf of the Board of Directors
For B S R & Co. LLP For Walker Chandiok & Co LLP M. S. Ramachandran R. K. Nair Sandeep Batra
Chartered Accountants Chartered Accountants Chairman Director Director
ICAI Firm Reg. No. 101248W/W-100022 ICAI Firm Reg. No. 001076N / N500013 DIN: 00943629 DIN: 07225354 DIN: 03620913
Kapil Goenka Sudhir N. Pillai Anup Bagchi Dhiren Salian Souvik Jash
Partner Partner Managing Director & CEO Chief Financial Officer Appointed Actuary
Membership No. 118189 Membership No. 105782 DIN: 00105962
Sonali Chandak
Place : Mumbai Company Secretary
Date : April 23, 2024
|